Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVRNASDAQ:APLTNASDAQ:CERONASDAQ:IFRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.56-4.1%$4.50$7.96▼$24.15$49.48M0.6316,643 shs69,539 shsAPLTApplied Therapeutics$0.35+3.1%$0.39$0.30▼$10.62$48.84M1.863.38 million shs1.08 million shsCEROCERo Therapeutics$11.50-42.0%$12.45$6.71▼$895.40$7.66M0.41286,885 shs3.01 million shsIFRXInflaRx$0.80+3.6%$1.27$0.71▼$2.82$51.69M1.29286,329 shs392,602 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-4.12%-16.88%-26.44%-77.68%-85.01%APLTApplied Therapeutics+1.59%-5.73%-23.12%-29.86%-92.21%CEROCERo Therapeutics-42.01%+55.83%-4.60%-40.10%-98.17%IFRXInflaRx+3.65%-4.19%-54.92%-36.67%-45.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AAPLTApplied Therapeutics4.2047 of 5 stars3.33.00.04.71.51.71.3CEROCERo Therapeutics2.932 of 5 stars3.23.00.00.02.30.80.0IFRXInflaRx3.5279 of 5 stars4.53.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AAPLTApplied Therapeutics 2.50Moderate Buy$6.101,640.37% UpsideCEROCERo Therapeutics 2.33Hold$140.001,117.39% UpsideIFRXInflaRx 3.00Buy$6.60727.07% UpsideCurrent Analyst Ratings BreakdownLatest ALVR, CERO, APLT, and IFRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025CEROCERo TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/30/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/29/2025IFRXInflaRxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$2.005/29/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $3.005/19/2025CEROCERo TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.005/14/2025APLTApplied TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.505/8/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.004/29/2025IFRXInflaRxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.004/22/2025CEROCERo TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/22/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$220.00 ➝ $220.003/26/2025IFRXInflaRxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AAPLTApplied Therapeutics$460K107.88N/AN/A$0.49 per share0.72CEROCERo TherapeuticsN/AN/AN/AN/A($41.98) per shareN/AIFRXInflaRx$180K297.61N/AN/A$1.13 per share0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)APLTApplied Therapeutics-$105.62M-$0.43N/AN/AN/AN/A-184.67%-84.02%8/6/2025 (Estimated)CEROCERo Therapeutics-$8.30MN/A0.00∞N/AN/AN/A-199.71%N/AIFRXInflaRx-$49.85M-$0.82N/AN/AN/A-33,362.70%-64.17%-53.39%8/6/2025 (Estimated)Latest ALVR, CERO, APLT, and IFRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/ACEROCERo TherapeuticsN/A-$31.80N/A-$1.59N/AN/A5/7/2025Q1 2025IFRXInflaRx-$0.18-$0.14+$0.04-$0.14$0.03 million$0.03 million4/14/2025Q4 2024APLTApplied Therapeutics-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million3/20/2025Q4 2024IFRXInflaRx-$0.27-$0.09+$0.18-$0.09$0.13 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACEROCERo TherapeuticsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78APLTApplied TherapeuticsN/A3.003.00CEROCERo TherapeuticsN/A0.730.73IFRXInflaRxN/A5.284.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%APLTApplied Therapeutics98.31%CEROCERo Therapeutics29.64%IFRXInflaRx42.39%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%APLTApplied Therapeutics1.60%CEROCERo Therapeutics12.72%IFRXInflaRx16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableAPLTApplied Therapeutics30141.58 million139.31 millionOptionableCEROCERo Therapeutics8390,000337,000N/AIFRXInflaRx6067.13 million56.19 millionOptionableALVR, CERO, APLT, and IFRX HeadlinesRecent News About These CompaniesInflaRx N.V. (NASDAQ:IFRX) Short Interest UpdateJune 18 at 4:40 AM | marketbeat.comCantor Fitzgerald Comments on InflaRx FY2026 EarningsJune 12, 2025 | americanbankingnews.comBrokers Issue Forecasts for InflaRx FY2026 EarningsJune 10, 2025 | marketbeat.comInflaRx (NASDAQ:IFRX) Sees Large Decline in Short InterestJune 4, 2025 | marketbeat.comInflaRx stock rating cut, price target slashed to $2 by Raymond JamesMay 30, 2025 | investing.comInflaRx Earnings Estimates, EPS & Revenue | NASDAQ:IFRX | BenzingaMay 30, 2025 | benzinga.comOppenheimer Has Lowered Expectations for InflaRx (NASDAQ:IFRX) Stock PriceMay 30, 2025 | marketbeat.comInflaRx’s Strategic Shift to INF904: A Promising Focus Amidst Early-Stage UncertaintyMay 29, 2025 | tipranks.comInflaRx N.V.: InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28, 2025 | finanznachrichten.dePG rating: Inflarx review declares phase III bombMay 28, 2025 | bioworld.comInflaRx ditches vilobelimab Phase III trial in PGMay 28, 2025 | thepharmaletter.comInflaRx plunges on plans to halt studies into lead asset in rare skin disorderMay 28, 2025 | msn.comInflaRx Stock (IFRX) Plummets 55% on Clinical FailureMay 28, 2025 | tipranks.comInflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin DiseaseMay 28, 2025 | benzinga.comInflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust CorpMay 28, 2025 | marketbeat.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma ...May 28, 2025 | gurufocus.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28, 2025 | globenewswire.comInflaRx to Participate in Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comInflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)May 11, 2025 | sg.finance.yahoo.comOppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform RecommendationMay 9, 2025 | msn.comOppenheimer Initiates Coverage on InflaRx (IFRX) with "Outperform" Rating | IFRX ...May 8, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALVR, CERO, APLT, and IFRX Company DescriptionsAlloVir NASDAQ:ALVR$2.56 -0.11 (-4.12%) As of 06/17/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Applied Therapeutics NASDAQ:APLT$0.35 +0.01 (+3.09%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.36 +0.01 (+2.14%) As of 06/18/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.CERo Therapeutics NASDAQ:CERO$11.50 -8.33 (-42.01%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$11.32 -0.18 (-1.60%) As of 06/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.InflaRx NASDAQ:IFRX$0.80 +0.03 (+3.65%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.80 0.00 (0.00%) As of 06/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
